

William T Curry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6241085/publications.pdf>

Version: 2024-02-01

88
papers

4,888
citations

147801

31
h-index

98798

67
g-index

88
all docs

88
docs citations

88
times ranked

8808
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	9.4	821
2	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. <i>Cancer Cell</i> , 2015, 28, 773-784.	16.8	327
3	Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. <i>International Forum of Allergy and Rhinology</i> , 2020, 10, 798-805.	2.8	284
4	Spinal epidural abscess: clinical presentation, management, and outcome. <i>World Neurosurgery</i> , 2005, 63, 364-371.	1.3	271
5	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. <i>Cancer Discovery</i> , 2014, 4, 1299-1309.	9.4	207
6	NCCN Guidelines Insights: Bone Cancer, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 155-167.	4.9	204
7	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv310.	6.3	182
8	Racial, Ethnic, and Socioeconomic Disparities in Patient Outcomes After Craniotomy for Tumor in Adult Patients in the United States, 1988-2004. <i>Neurosurgery</i> , 2010, 66, 427-438.	1.1	167
9	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 5799-5807.	7.0	166
10	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 2898-2909.	7.0	146
11	Rapidly Rising Incidence of Cerebrospinal Fluid Shunting Procedures for Idiopathic Intracranial Hypertension in the United States, 1988-2002. <i>Neurosurgery</i> , 2005, 57, 97-108.	1.1	122
12	Airborne Aerosol Generation During Endonasal Procedures in the Era of COVID-19: Risks and Recommendations. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 465-470.	1.9	118
13	Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. <i>Journal of Neuro-Oncology</i> , 2009, 93, 25-39.	2.9	116
14	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 4452-4465.	7.0	112
15	Craniotomy for meningioma in the United States between 1988 and 2000: decreasing rate of mortality and the effect of provider caseload. <i>Journal of Neurosurgery</i> , 2005, 102, 977-986.	1.6	103
16	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now235.	1.2	99
17	Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. <i>Neuro-Oncology</i> , 2016, 18, 863-872.	1.2	91
18	Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. <i>Journal of Neurosurgery</i> , 2016, 124, 106-114.	1.6	86

#	ARTICLE	IF	CITATIONS
19	Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1490-1496.	1.5	76
20	Postoperative Intensive Care Unit Requirements After Elective Craniotomy. <i>World Neurosurgery</i> , 2014, 81, 165-172.	1.3	73
21	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015, 1, 662.	7.1	68
22	Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells. <i>Neuro-Oncology</i> , 2018, 20, 44-54.	1.2	51
23	<i>TERT</i> Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 169-178.	7.0	50
24	Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. <i>Radiotherapy and Oncology</i> , 2019, 137, 95-101.	0.6	46
25	Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2016, 22, 2885-2896.	7.0	45
26	Immediate and Delayed Complications Following Endoscopic Skull Base Surgery. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2015, 76, 390-396.	0.8	43
27	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	7.1	40
28	Esthesioneuroblastoma: An Update on the Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital Experience with Craniofacial Resection, Proton Beam Radiation, and Chemotherapy. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2014, 75, 058-064.	0.8	37
29	Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. <i>Journal of Neurosurgery</i> , 2018, 128, 1123-1132.	1.6	37
30	Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma. <i>Oncolmmunology</i> , 2019, 8, e1577108.	4.6	35
31	Blockade of transforming growth factor- β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. <i>International Journal of Cancer</i> , 2017, 141, 2348-2358.	5.1	33
32	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. <i>Nature Communications</i> , 2022, 13, 1325.	12.8	31
33	An Algorithm for Surgical Approach to the Anterior Skull Base. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2016, 77, 364-370.	0.8	29
34	A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. <i>Neurosurgery</i> , 2019, 85, 204-210.	1.1	28
35	Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 252-266.	0.8	28
36	Stereotactic interstitial radiosurgery for cerebral metastases. <i>Journal of Neurosurgery</i> , 2005, 103, 630-635.	1.6	27

#	ARTICLE	IF	CITATIONS
37	Immunomodulation: checkpoint blockade etc.: Fig. 1.. Neuro-Oncology, 2015, 17, vii26-vii31.	1.2	26
38	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clinical Cancer Research, 2019, 25, 4375-4387.	7.0	26
39	IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. OncoImmunology, 2020, 9, 1806662.	4.6	26
40	The impact of surgery on survival after progression of glioblastoma: A retrospective cohort analysis of a contemporary patient population. Journal of Clinical Neuroscience, 2018, 53, 41-47.	1.5	24
41	Vascularized Fibular Strut Autografts in Spinal Reconstruction after Resection of Vertebral Chordoma or Chondrosarcoma: A Retrospective Series. Neurosurgery, 2017, 81, 156-164.	1.1	23
42	Factors that modify the risk of intraoperative seizures triggered by electrical stimulation during supratentorial functional mapping. Clinical Neurophysiology, 2019, 130, 1058-1065.	1.5	22
43	A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.. Journal of Clinical Oncology, 2014, 32, 2005-2005.	1.6	22
44	(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas. Translational Cancer Research, 2019, 8, S167-S170.	1.0	22
45	Outcomes and patterns of care in adult skull base chondrosarcomas from the SEER database. Journal of Clinical Neuroscience, 2014, 21, 1497-1502.	1.5	21
46	Brachytherapy as an Adjuvant for Recurrent Atypical and Malignant Meningiomas. Neurosurgery, 2019, 85, E910-E916.	1.1	20
47	Neural encoding and production of functional morphemes in the posterior temporal lobe. Nature Communications, 2018, 9, 1877.	12.8	18
48	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunology Research, 2022, 10, 996-1012.	3.4	18
49	Delayed Endovascular Coil Extrusion following Internal Carotid Artery Embolization. Journal of Neurological Surgery Reports, 2014, 75, e255-e258.	0.6	16
50	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist, 2019, 24, 193-201.	3.7	16
51	Delayed Complications after Anterior Craniofacial Resection of Malignant Skull Base Tumors. Journal of Neurological Surgery, Part B: Skull Base, 2014, 75, 110-116.	0.8	15
52	Aseptic Meningitis with Craniopharyngioma Resection: Consideration after Endoscopic Surgery. Journal of Neurological Surgery Reports, 2016, 77, e151-e155.	0.6	15
53	SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.. Journal of Clinical Oncology, 2019, 37, 2016-2016.	1.6	14
54	A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood, 2021, 138, 382-386.	1.4	13

#	ARTICLE	IF	CITATIONS
55	IDH mutational status and the immune system in gliomas: a tale of two tumors?. <i>Translational Cancer Research</i> , 2017, 6, S1253-S1256.	1.0	13
56	Isocitrate Dehydrogenase Mutations in Low-Grade Gliomas Correlate With Prolonged Overall Survival in Older Patients. <i>Neurosurgery</i> , 2019, 84, 519-528.	1.1	11
57	Orbital Preservation in Patients with Esthesioneuroblastoma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2013, 74, 142-145.	0.8	10
58	Implications of IDH mutations on immunotherapeutic strategies for malignant glioma. <i>Neurosurgical Focus</i> , 2022, 52, E6.	2.3	10
59	A Rare Finding of Schwannoma of the Vidian Canal: A Case Report. <i>Journal of Neurological Surgery Reports</i> , 2015, 76, e48-e51.	0.6	8
60	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. <i>Journal of Clinical Neuroscience</i> , 2016, 31, 99-105.	1.5	8
61	Comparative evaluation of methylene blue and demeclocycline for enhancing optical contrast of gliomas in optical images. <i>Journal of Biomedical Optics</i> , 2014, 19, 090504.	2.6	7
62	Phantomia and Dysgeusia following Endoscopic Transcribriform Approaches to Olfactory Groove Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 38, 245-250.	0.8	7
63	Meningoencephalocele and Cerebrospinal Fluid Leak Complicating Orbital Decompression. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, e79-e81.	0.8	6
64	Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting. <i>Frontiers in Pharmacology</i> , 2021, 12, 660841.	3.5	6
65	Intraoperative thalamocortical tract monitoring via direct cortical recordings during craniotomy. <i>Clinical Neurophysiology</i> , 2021, 132, 1416-1432.	1.5	6
66	Navigable Channel-Based Trans-Sulcal Resection of Third Ventricular Colloid Cysts: A Multicenter Retrospective Case Series and Review of the Literature. <i>World Neurosurgery</i> , 2020, 133, e702-e710.	1.3	5
67	Neurophysiologic Mapping of Thalamocortical Tract in Asleep Craniotomies: Promising Results From an Early Experience. <i>Operative Neurosurgery</i> , 2021, 20, 219-225.	0.8	5
68	Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. <i>World Neurosurgery</i> , 2020, 133, e804-e812.	1.3	4
69	Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations. <i>Neurologia Medico-Chirurgica</i> , 2021, 61, 385-391.	2.2	4
70	A Common Rule for Resection of Glioblastoma in the Molecular Era. <i>JAMA Oncology</i> , 2020, 6, 503.	7.1	3
71	Microsurgical resection of foramen magnum meningioma: multi-institutional retrospective case series and proposed surgical risk scoring system. <i>Journal of Neuro-Oncology</i> , 2021, 153, 331-342.	2.9	3
72	Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2041-2041.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Phase 2 trial of baviximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2030-2030.	1.6	3
74	Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2037-2037.	1.6	3
75	Perspectives on investigational drugs and immunotherapies for glioblastoma. Expert Opinion on Investigational Drugs, 2016, 25, 1007-1009.	4.1	2
76	Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.. Journal of Clinical Oncology, 2015, 33, 2036-2036.	1.6	2
77	HER2 positivity in brain metastases from gastrointestinal primary malignancies.. Journal of Clinical Oncology, 2018, 36, 61-61.	1.6	1
78	The New England Neurosurgical Society: growth and evolution over 70 years. Journal of Neurosurgery, 2023, 138, 261-269.	1.6	1
79	Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience. Neuro-Oncology, 2022, 24, 2180-2189.	1.2	1
80	EXTH-14. THE ALKYLATING CHEMOTHERAPEUTIC TEMOZOLOMIDE INDUCES METABOLIC STRESS AND POTENTIATES NAD+ DEPLETION-MEDIATED CELL DEATH IN IDH1 MUTANT CANCERS. Neuro-Oncology, 2017, 19, vi75-vi75.	1.2	0
81	IMMU-64. TRIPLE COMBINATION IMMUNOTHERAPY WITH VACCINATION, PD-1 BLOCKADE, AND OX40 LIGATION IS HIGHLY EFFECTIVE AGAINST MURINE INTRACRANIAL GLIOMA. Neuro-Oncology, 2017, 19, vi127-vi127.	1.2	0
82	Case 10-2021: A 70-Year-Old Man with Depressed Mood, Unsteady Gait, and Urinary Incontinence. New England Journal of Medicine, 2021, 384, 1350-1358.	27.0	0
83	Targetable signaling pathway mutations and progression of <i>IDH</i>-mutant glioma.. Journal of Clinical Oncology, 2014, 32, 2061-2061.	1.6	0
84	ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells.. Journal of Clinical Oncology, 2014, 32, e13022-e13022.	1.6	0
85	Brachytherapy for Recurrent High-grade Meningiomas: An Institutional Experience. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.8	0
86	Characterizing glioma microenvironment with ultra-high gradient diffusion MRI.. Journal of Clinical Oncology, 2017, 35, 2050-2050.	1.6	0
87	MRI changes in patients with newly diagnosed glioblastoma treated as part of a phase II trial with baviximab, radiation, and temozolomide.. Journal of Clinical Oncology, 2020, 38, 2546-2546.	1.6	0
88	Reversal of Intracranial Hypertensionâ€Related Pseudomeningocele after Venous Sinus Stenting. , 2022, 2, .		0